The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Establishes distribution center in top hub for international shipping
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
Subscribe To Our Newsletter & Stay Updated
